Deborah Morosini - Nov 16, 2021 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
EVP, Chief of Clinical Affairs
Signature
/s/ Brian Piper, Attorney-in-Fact
Stock symbol
PRLD
Transactions as of
Nov 16, 2021
Transactions value $
-$87,081
Form type
4
Date filed
11/18/2021, 05:42 PM
Previous filing
Jul 22, 2021
Next filing
Dec 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRLD Common Stock Options Exercise $369K +28.8K +6475.45% $12.85 29.2K Nov 16, 2021 Direct
transaction PRLD Common Stock Sale -$450K -28.4K -97.11% $15.87 844 Nov 16, 2021 Direct F1, F2
transaction PRLD Common Stock Sale -$6.57K -400 -47.39% $16.43 444 Nov 16, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Employee Stock Option (right to buy) Options Exercise $0 -28.8K -12.79% $0.00 196K Nov 16, 2021 Common Stock 28.8K $12.85 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.41 to $16.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.41 to $16.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4 The stock option vested as to 25% of the total shares monthly beginning on July 27, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.